Physician profile
Elizabeth A Larson
NPI 1174510564
$1,269.78
in general payments reported to CMS, 2019-2025
26 companies · $150 in 2025
The $150 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $34.01 · 2021: $166 · 2022: $285 · 2023: $216 · 2024: $262 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $628.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $316.83 | 2021-2025 | Qelbree, Qelbree |
| Pfizer INC. | $79.78 | 2021-2023 | |
| Sanofi Pasteur INC. | $74.55 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $74.35 | 2022-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Kaleo, INC. | $63.90 | 2019-2024 | Auvi-Q |
| Neos Therapeutics, LP | $63.50 | 2020-2025 | Cotempla Xr-Odt |
| Alk-Abello, INC | $62.60 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $55.86 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.73 | 2019 | |
| Genentech USA, INC. | $43.87 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $43.17 | 2024 | Flumist Quadrivalent |
| Tris Pharma INC | $40.67 | 2023-2024 | Dyanavel Xr |
| Glaxosmithkline, LLC. | $38.72 | 2019-2024 | Bexsero |
| Ironshore Pharmaceuticals INC. | $38.62 | 2020-2024 | |
| Shire North American Group INC | $29.42 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $22.94 | 2021 | |
| Kyowa Kirin, INC. | $20.57 | 2023 | Crysvita |
| Novartis Pharmaceuticals Corporation | $20.42 | 2019 | |
| Corium, LLC | $20.02 | 2022 | |
| Lnhc, INC | $18.74 | 2025 | Zelsuvmi |
| Hologic Sales and Service, LLC | $18.60 | 2019 | |
| Sarepta Therapeutics, INC. | $16.93 | 2022 | |
| Biomarin Pharmaceutical INC. | $16.85 | 2023 | Voxzogo 1.2mg |
| Ultragenyx Pharmaceutical INC. | $16.03 | 2023 | |
| Collegium Pharmaceutical, INC. | $13.46 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $12.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Larson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.